Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
Rhea-AI Summary
Microbot Medical (Nasdaq: MBOT) signed a Letter of Agreement with Sanmina to manufacture the LIBERTY Endovascular Robotic System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
The deal adds a second manufacturing site, aimed at boosting capacity, supporting global expansion, and, according to Microbot, improving operating efficiencies, lowering costs, and expanding gross margins as LIBERTY adoption grows in the U.S. and internationally.
Positive
- LOA with Sanmina adds a second manufacturing site for LIBERTY
- Manufacturing expansion supports rising U.S. and international LIBERTY demand
- Company targets lower costs and expanded gross margins via Sanmina partnership
- Sanmina’s global footprint may support future LIBERTY production scale-up
- Manufacturing move aligns with stated company cost reduction strategy
Negative
- None.
News Market Reaction – MBOT
On the day this news was published, MBOT gained 4.28%, reflecting a moderate positive market reaction. This price movement added approximately $5M to the company's valuation, bringing the market cap to $125.60M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Industry award | Positive | -1.1% | LIBERTY System wins 2026 Innovative Start-Up Award, highlighting industry recognition. |
| Jun 23 | Pennsylvania adoption | Positive | -1.6% | First Pennsylvania health system adopts LIBERTY, expanding Eastern U.S. footprint. |
| Jun 16 | Federal access deal | Positive | +0.0% | Lovell Government Services agreement to open LIBERTY access across U.S. federal systems. |
| Jun 09 | Michigan adoption | Positive | -2.5% | First major Michigan health system adopts LIBERTY, first Midwest commercial account. |
| Jun 02 | First NC customer | Positive | +1.5% | First North Carolina academic health system adopts LIBERTY, broadening U.S. presence. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive commercial and adoption updates have often been followed by flat-to-negative next-day price moves.
Key Terms
endovascular medical
ce mark regulatory
gross margins financial
federal supply schedule regulatory
form s-3 regulatory
rule 473(b) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expanding manufacturing capabilities is part of the Company’s cost reduction strategy and supports global expansion
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. As momentum continues to rise in the U.S., reflected in increased accounts and usage across several states, and with the momentum building in the international markets as seen with the recent clearance in Israel and progress towards obtaining CE Mark as well as registration in additional markets, the Company believes it is necessary to expand its manufacturing capacity to meet expected demand from existing and new accounts as well as to support its cost reduction strategy.
“We are pleased and excited to mark the signing of this agreement,” said Asaf Shemesh, CEO, Sanmina Israel. “We are confident in the value of this partnership and what it represents for both organizations moving forward. We are eager and ready to support LIBERTY as it continues to grow and achieve its strategic objectives, while working together to ensure a successful and productive path forward.”
In addition to serving as a second site that diversifies the Company’s manufacturing capabilities, the Company expects it will improve operating efficiencies, lower costs, and expand gross margins. Furthermore, as one of the largest contract manufacturers globally, Sanmina has sites across many regions which could be beneficial as the Company scales production to meet anticipated demand over the next couple of years.
“As the pace of adoption continues to gain momentum, with several accounts across the Eastern U.S. increasing their utilization of the LIBERTY System and additional accounts in our existing and new sales territories are advancing in the sales funnel, we believe Sanmina will allow us to increase our manufacturing capacity and enable us to drive greater efficiency while addressing market demand for the foreseeable future,” commented Michal Ahuvia, Director of Operations. “With plans to increase our sales footprint to the Western U.S. later this year, along with recent clearance in Israel and current expectations for obtaining the CE Mark and other registrations, we believe securing a long-term partnership with a global leader like Sanmina positions us to meet expected near and long-term customer demand.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
